Journal
CLINICAL CASE REPORTS
Volume 6, Issue 4, Pages 698-701Publisher
WILEY
DOI: 10.1002/ccr3.1446
Keywords
Acute ischemic stroke; dabigatran etexilate; idarucizumab; thrombectomy; thrombolysis
Categories
Ask authors/readers for more resources
Key Clinical Message Patients presenting with an acute ischemic stroke despite dabigatran therapy (last intake <24 h or unknown) should be evaluated for reversal by idarucizumab, making them eligible for safe and effective intravenous thrombolysis. It has been shown to be feasible, well-tolerated, and easy to manage in an emergency room or stroke unit.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available